Comparing VolitionRx (NYSE:VNRX) and Myriad Genetics (NASDAQ:MYGN)
Comparing VolitionRx (NYSE:VNRX) and Myriad Genetics (NASDAQ:MYGN)
VolitionRx (NYSE:VNRX – Get Rating) and Myriad Genetics (NASDAQ:MYGN – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.
VolitionRx(NYSE：VNRX-GET Rating)和Myriad Genetics(纳斯达克：MYGN-GET Rating)都是医疗公司，但哪只股票更优越？我们将根据两家公司的分析师建议、风险、估值、股息、盈利能力、收益和机构所有权的强弱对它们进行比较。
Volatility & Risk
波动性与风险
VolitionRx has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500.
VolitionRx的贝塔系数为1.62，表明其股价的波动性比标准普尔500指数高出62%。相比之下，Myriad Genetics的贝塔系数为1.7，这表明其股价的波动性比标准普尔500指数高70%。
Valuation & Earnings
估值与收益
This table compares VolitionRx and Myriad Genetics' gross revenue, earnings per share (EPS) and valuation.
该表格比较了VolitionRx和Myriad Genetics的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VolitionRx | $90,000.00 | 1,254.17 | -$26.82 million | ($0.56) | -3.52 |
| Myriad Genetics | $690.60 million | 3.14 | -$27.20 million | ($0.24) | -112.12 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 誓言Rx | $90,000.00 | 1,254.17 | -2,682万元 | ($0.56) | -3.52 |
| 无数种遗传学 | 6.906亿美元 | 3.14 | -2,720万元 | ($0.24) | -112.12 |
Profitability
盈利能力
This table compares VolitionRx and Myriad Genetics' net margins, return on equity and return on assets.
下表比较了VolitionRx和Myriad Genetics的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| VolitionRx | -15,698.45% | -226.46% | -107.31% |
| Myriad Genetics | -2.62% | -3.44% | -2.57% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 誓言Rx | -15,698.45% | -226.46% | -107.31% |
| 无数种遗传学 | -2.62% | -3.44% | -2.57% |
Insider & Institutional Ownership
内部人与机构所有权
11.1% of VolitionRx shares are held by institutional investors. Comparatively, 97.4% of Myriad Genetics shares are held by institutional investors. 16.0% of VolitionRx shares are held by company insiders. Comparatively, 1.8% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
VolitionRx 11.1%的股份由机构投资者持有。相比之下，Myriad Genetics 97.4%的股份由机构投资者持有。VolitionRx 16.0%的股份由公司内部人士持有。相比之下，Myriad Genetics 1.8%的股份由公司内部人士持有。强大的机构持股表明，大型基金管理公司、捐赠基金和对冲基金相信，一只股票的长期表现将好于大盘。
Analyst Ratings
分析师评级
This is a breakdown of current recommendations and price targets for VolitionRx and Myriad Genetics, as provided by MarketBeat.
这是MarketBeat提供的VolitionRx和Myriad Genetics的当前建议和目标价的细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VolitionRx | 0 | 0 | 0 | 0 | N/A |
| Myriad Genetics | 1 | 1 | 0 | 0 | 1.50 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 誓言Rx | 0 | 0 | 0 | 0 | 不适用 |
| 无数种遗传学 | 1 | 1 | 0 | 0 | 1.50 |
Myriad Genetics has a consensus target price of $28.33, indicating a potential upside of 5.29%. Given Myriad Genetics' higher possible upside, analysts clearly believe Myriad Genetics is more favorable than VolitionRx.
Myriad Genetics的共识目标价为28.33美元，表明潜在上行5.29%。考虑到Myriad Genetics更有可能的上行空间，分析师们显然认为Myriad Genetics比VolitionRx更有利。
Summary
摘要
Myriad Genetics beats VolitionRx on 8 of the 12 factors compared between the two stocks.
与VolitionRx相比，Myriad Genetics在12个因素中有8个击败了VolitionRx。
About VolitionRx
关于VolitionRx
(Get Rating)
(获取评级)
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
VolitionRx有限公司是一家跨国表观遗传学公司，致力于开发血液测试，以帮助诊断全球范围内的一系列癌症和其他疾病。它销售检测癌症的Nu.Q；监测免疫系统的Nu.Q Nets；用于兽医应用的Nu.Q Vet癌症筛查测试；Nu.Q Capture捕获和浓缩样本以进行更准确的诊断；以及Nu.Q Discover，一种分析核小体的解决方案。该公司运营的是血液检测技术平台--核糖体。VolitionRx有限公司总部设在德克萨斯州奥斯汀。
About Myriad Genetics
关于Myriad Genetics
(Get Rating)
(获取评级)
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Myriad Genetics，Inc.是一家基因测试和精密药物公司，在美国和国际上开发基因测试并将其商业化。该公司提供分子诊断测试，用于肿瘤学、妇女和心理健康应用。它提供了MyRisk遗传性癌症测试，这是一种评估遗传性癌症风险的DNA测序测试；BRAC分析CDX种系伴随诊断测试，这是一种DNA测序测试，有助于确定转移性乳腺癌、卵巢癌、转移性胰腺癌或转移性前列腺癌患者的治疗方案，这些患者具有有害或疑似有害的种系BRCA变异；以及MyChoice CDX伴生诊断测试，这是一种肿瘤测试，可以确定卵巢癌患者的同源重组缺陷状态。该公司还提供Prolaris前列腺癌预后测试，这是一种评估前列腺癌侵袭性的RNA表达肿瘤分析；EndoPredict乳腺癌预后测试，这是一种评估乳腺癌侵袭性的RNA表达测试；Prequel Tumor，一种精确肿瘤学的解决方案；以及Prequel Prenatus Screen，一种使用母体血液进行的非侵入性产前筛查测试，以筛查胎儿中的严重染色体疾病。此外，它还提供Foresight Carrier Screen，这是一种为未来父母提供的产前测试，以评估他们将隐性遗传疾病遗传给后代的风险；以及GeneSight精神病精神健康药物测试，这是一种DNA基因分型测试，可帮助患有抑郁症、焦虑症、ADHD和其他精神健康疾病的患者选择精神药物。Myriad Genetics，Inc.与Illumina，Inc.和InterMountain Precision Gentics公司建立了战略合作关系，提供生殖系和体细胞肿瘤检测服务。该公司成立于1991年，总部设在犹他州盐湖城。
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.
接收VolitionRx日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对VolitionRx和相关公司的最新新闻和分析师评级的每日简要摘要。